Delivery Order SPE2DB22D3004-SPE2DB24FPF73

Award Date 2/7/24
Potential Completion Date 2/8/24
Potential Value $9.7K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has been awarded a firm fixed price delivery order by the Defense Logistics Agency (DLA) to provide RABAVERT Rabies Vaccine with diluents. The $9,651.50 award has a performance period through March 5, 2024 and does not utilize any set-aside designations. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which falls under a larger indefinite delivery contract (IDC) with DLA valued up to...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a $1,930.30 firm fixed price delivery order by the Defense Logistics Agency (DLA) to provide RABAVERT rabies vaccine with diluents. The delivery order has a completion date of March 7, 2024 and does not include a set-aside designation. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) awarded by DLA with a potential value of $999,999,999.00 and a performance period...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a firm fixed price delivery order from the Defense Logistics Agency (DLA) to provide $5,359.12 worth of RABAVERT rabies vaccine with diluents. This award is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, valued at up to $999,999,999.00 through December 2025, to deliver pharmaceutical products and medical supplies to support military treatment programs and...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a firm fixed price delivery order contract worth $3,860.60 by the Defense Logistics Agency (DLA) to provide RABAVERT rabies vaccine and diluents. The delivery order has a completion date of February 14, 2024. This award is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds with the DLA to deliver pharmaceutical products and...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of RABAVERT rabies vaccine with diluents. The contract has a ceiling value of $15,442.40 and a period of performance through April 15, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is part of a larger indefinite delivery contract (IDC) with DLA valued at up to...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $9,651.50 to provide RABAVERT rabies vaccine with diluents. This award is part of Amerisourcebergen's broader contract vehicle with DLA, an indefinite delivery contract (IDC) valued at up to $999,999,999.00 through December 31, 2025, to deliver a wide range of pharmaceutical products and medical supplies to DLA Troop...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide RABAVERT RABIES VACC W-DILUENTS. The contract has a potential value of $1,930.30 and a completion date of February 12, 2024. Amerisourcebergen Drug Corp is the prime contractor and no set-aside was used for this award. Amerisourcebergen Drug Corp also holds an indefinite delivery contract (IDC) with DLA, valued at up to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide RABAVERT rabies vaccine with diluents. The $38,606.00 delivery order has a completion date of February 27, 2024. Amerisourcebergen Drug Corp, a for-profit organization, is the prime contractor on an indefinite delivery contract (IDC) valued up to $999,999,999.00 with DLA to deliver pharmaceutical products and medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office Division. The $1,930.30 firm-fixed-price contract is for the supply of RABAVERT rabies vaccine with diluent. The order has a completion date of July 19, 2024. Amerisourcebergen is a major pharmaceutical distributor that provides a wide range of medical products and supplies to federal agencies, including the military. The company holds several Indefinite Delivery...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide RABAVERT rabies vaccine with diluents. The $2,895.45 order has a completion date of March 6, 2024 and was awarded on March 5, 2024. Amerisourcebergen Drug Corp is the prime contractor and serves as a key pharmaceutical supplier to DLA, holding a $999,999,999.00 indefinite delivery contract to deliver a...
  • SPE2DB22D3004
    Indefinite Delivery Contract
  • SPE2DB22D3004-SPE2DB24FPF73
    Delivery Order

Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, was awarded a $9,651.50 firm fixed price delivery order by the Defense Logistics Agency (DLA) to provide RABAVERT rabies vaccine with diluents. This delivery order does not have a set-aside designation and is scheduled for completion by February 8, 2024. Amerisourcebergen Drug Corp serves as the prime contractor for this award, which is issued under an indefinite delivery contract (IDC) they hold with DLA. The IDC has a potential value of $999,999,999.00 and a performance period through December 31, 2025, enabling Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment programs and facilities worldwide.

Generated 5/8/24, 10:37 AM